Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization
Background: We aimed to compare human menopausal gonadotropin (hMG) and recombinant follicle-stimulating hormone (r FSH) with respect to clinical outcomes and the development of ovarian hyperstimulation syndrome (OHSS) for patients with polycystic ovary syndrome (PCOS) treated with in vitro fert...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Royan Institute (ACECR), Tehran
2013-01-01
|
Series: | International Journal of Fertility and Sterility |
Subjects: | |
Online Access: | http://www.ijfs.ir/article_45152_efb0ee8a85dcd7933348f4a4d2ebc63e.pdf |
id |
doaj-8ca13b18b65f46c5b7e51ab48dffb2d1 |
---|---|
record_format |
Article |
spelling |
doaj-8ca13b18b65f46c5b7e51ab48dffb2d12020-11-25T04:05:26ZengRoyan Institute (ACECR), TehranInternational Journal of Fertility and Sterility2008-076X2008-07782013-01-016423824345152Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro FertilizationAyse Figen Turkcapar0Berna Seckin1Gogsen Onalan2Tulin Ozdener3Sertac Batioglu4Department of Reproductive Endocrinology, Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, TurkeyDepartment of Reproductive Endocrinology, Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, TurkeyDepartment of Obstetrics and Gynecology, Baskent University School of Medicine, Ankara, TurkeyDepartment of Reproductive Endocrinology, Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, TurkeyDepartment of Reproductive Endocrinology, Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, TurkeyBackground: We aimed to compare human menopausal gonadotropin (hMG) and recombinant follicle-stimulating hormone (r FSH) with respect to clinical outcomes and the development of ovarian hyperstimulation syndrome (OHSS) for patients with polycystic ovary syndrome (PCOS) treated with in vitro fertilization (IVF). Materials and Methods: This prospective randomized controlled trial included a total of 80 women with PCOS. Of these, 38 were randomized to receive treatment with hMG and 42 with rFSH using a long gonadotropin releasing hormone (GnRH) analogue protocol. Outcome measures were cycle characteristics, pregnancy rates, the need for coasting, and OHSS rates. Results: In the hMG group we observed a significantly lower peak estradiol (E2) level (p=0.02), fewer intermediate-sized follicles (p=0.001), lower number of oocytes retrieved (p=0.002) and metaphase II (MII) oocytes (p=0.003). However, there were no significant differences between the groups in the number of fertilized oocytes, fertilization rates, top quality embryo counts, and the number of transferred embryos. There was no difference in pregnancy rates between the groups. OHSS occurred in 11.9% of the rFSH group patients, whereas no OHSS developed in the hMG group. Coasting requirements were lower in the hMG group (19.2% vs. 48.9%, p=0.013). Conclusion: Ovarian stimulation with hMG and rFSH provides similar clinical pregnancy rates in PCOS patients treated with a long GnRH agonist protocol in IVF cycles. hMG stimulation appears to be associated with a lower rate of OHSS and decreased coasting requirements (Registration Number: NCT01365936).http://www.ijfs.ir/article_45152_efb0ee8a85dcd7933348f4a4d2ebc63e.pdfhmgrecombinant fshfertilizationpolycystic ovary syndrome |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ayse Figen Turkcapar Berna Seckin Gogsen Onalan Tulin Ozdener Sertac Batioglu |
spellingShingle |
Ayse Figen Turkcapar Berna Seckin Gogsen Onalan Tulin Ozdener Sertac Batioglu Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization International Journal of Fertility and Sterility hmg recombinant fsh fertilization polycystic ovary syndrome |
author_facet |
Ayse Figen Turkcapar Berna Seckin Gogsen Onalan Tulin Ozdener Sertac Batioglu |
author_sort |
Ayse Figen Turkcapar |
title |
Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization |
title_short |
Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization |
title_full |
Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization |
title_fullStr |
Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization |
title_full_unstemmed |
Human Menopausal Gonadotropin versus Recombinant FSH in Polycystic Ovary Syndrome Patients Undergoing In Vitro Fertilization |
title_sort |
human menopausal gonadotropin versus recombinant fsh in polycystic ovary syndrome patients undergoing in vitro fertilization |
publisher |
Royan Institute (ACECR), Tehran |
series |
International Journal of Fertility and Sterility |
issn |
2008-076X 2008-0778 |
publishDate |
2013-01-01 |
description |
Background: We aimed to compare human menopausal gonadotropin (hMG) and recombinant follicle-stimulating hormone (r FSH) with respect to clinical outcomes and the development of ovarian hyperstimulation syndrome (OHSS) for patients with polycystic ovary syndrome (PCOS) treated with in vitro fertilization (IVF). Materials and Methods: This prospective randomized controlled trial included a total of 80 women with PCOS. Of these, 38 were randomized to receive treatment with hMG and 42 with rFSH using a long gonadotropin releasing hormone (GnRH) analogue protocol. Outcome measures were cycle characteristics, pregnancy rates, the need for coasting, and OHSS rates. Results: In the hMG group we observed a significantly lower peak estradiol (E2) level (p=0.02), fewer intermediate-sized follicles (p=0.001), lower number of oocytes retrieved (p=0.002) and metaphase II (MII) oocytes (p=0.003). However, there were no significant differences between the groups in the number of fertilized oocytes, fertilization rates, top quality embryo counts, and the number of transferred embryos. There was no difference in pregnancy rates between the groups. OHSS occurred in 11.9% of the rFSH group patients, whereas no OHSS developed in the hMG group. Coasting requirements were lower in the hMG group (19.2% vs. 48.9%, p=0.013). Conclusion: Ovarian stimulation with hMG and rFSH provides similar clinical pregnancy rates in PCOS patients treated with a long GnRH agonist protocol in IVF cycles. hMG stimulation appears to be associated with a lower rate of OHSS and decreased coasting requirements (Registration Number: NCT01365936). |
topic |
hmg recombinant fsh fertilization polycystic ovary syndrome |
url |
http://www.ijfs.ir/article_45152_efb0ee8a85dcd7933348f4a4d2ebc63e.pdf |
work_keys_str_mv |
AT aysefigenturkcapar humanmenopausalgonadotropinversusrecombinantfshinpolycysticovarysyndromepatientsundergoinginvitrofertilization AT bernaseckin humanmenopausalgonadotropinversusrecombinantfshinpolycysticovarysyndromepatientsundergoinginvitrofertilization AT gogsenonalan humanmenopausalgonadotropinversusrecombinantfshinpolycysticovarysyndromepatientsundergoinginvitrofertilization AT tulinozdener humanmenopausalgonadotropinversusrecombinantfshinpolycysticovarysyndromepatientsundergoinginvitrofertilization AT sertacbatioglu humanmenopausalgonadotropinversusrecombinantfshinpolycysticovarysyndromepatientsundergoinginvitrofertilization |
_version_ |
1724433951433424896 |